Collaborators share first ALK2 protein structure bound to M4K Pharma compound A: The overall structure of ALK2 bound to M4K2117. B: The structure of the ligand M4K2117. C: A close up of the binding pocket of ALK2 bound to M4K2117 (From: https://openlabnotebooks.org/deposition-of-structure-of-alk2-with-m4k2117/). M4K Pharma's collaborators Dr Alex Bullock and his team from the Structural Genomics Consortium [...]
Fostering open collaboration in drug development for paediatric brain tumours Wong et al. describe in Biochemical Society Transactions how open collaboration and an open drug discovery model, like the one used by M4K Pharma, can help overcome the challenges faced while researching therapies for rare paediatric brain tumours such as DIPG. Prognosis of childhood brain [...]
Listen to a recording of the Sept 2019 Monthly Scientific Meeting Listen to M4K Pharma's Scientific Update Meeting from September 12th, 2019 where our scientists and collaborators discuss the latest progress in our Medicines4Kids project for a deadly children's brain cancer called DIPG. Everyone is invited to hear first-hand how we are [...]
